A real-world pharmacovigilance assessment and literature review of lymphoma development in lipodystrophy
Metreleptin is a form of leptin replacement therapy used with diet and lifestyle modifications to treat the metabolic complications of leptin deficiency in lipodystrophy, a rare disease characterized by adipose tissue deficiency. Previously, identification of T-cell lymphomas in three metreleptin-tr...
Gespeichert in:
| Veröffentlicht in: | Frontiers in endocrinology (Lausanne) Jg. 16; S. 1582715 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Switzerland
Frontiers Media S.A
21.05.2025
|
| Schlagworte: | |
| ISSN: | 1664-2392, 1664-2392 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Metreleptin is a form of leptin replacement therapy used with diet and lifestyle modifications to treat the metabolic complications of leptin deficiency in lipodystrophy, a rare disease characterized by adipose tissue deficiency. Previously, identification of T-cell lymphomas in three metreleptin-treated patients with acquired generalized lipodystrophy (AGL) suggested a possible relationship between metreleptin and lymphoma development. To further investigate this, we performed a real-world pharmacovigilance assessment and literature review to identify lymphomas in patients with lipodystrophy and congenital leptin deficiency (CLD) who were either metreleptin-naïve, or who had previously received/were receiving metreleptin at the time of lymphoma diagnosis.
Cases were identified from PubMed, Embase and the Cochrane Library (from database inception through to November 22, 2024), and through review of 11 years post-marketing data from the global safety database (GSD) of the marketing authorization holder for metreleptin.
The final analysis set comprised 17 lymphomas in 16 patients reported in 11 published articles and one GSD case report. Twelve lymphomas were recorded in 12 metreleptin-naïve patients - these comprised six T-cell lymphomas (one each in six patients with AGL), three B-cell lymphomas (in two patients with familial partial lipodystrophy and one patient with AGL), and three Hodgkin lymphomas (separately reported in one patient each with generalized lipodystrophy, juvenile-onset dermatomyositis-associated lipodystrophy, and CLD). Five lymphomas were identified in four metreleptin-treated patients, three of whom (all with AGL and T-cell lymphomas) were reported in previously published studies. The remaining metreleptin-treated patient (from the GSD) had generalized lipodystrophy-associated atypical progeroid syndrome and developed a B-cell lymphoma and brain lymphoma following solid organ transplantation and immunosuppressant therapy. All nine T-cell lymphomas occurred in patients with AGL, and additional autoimmune and/or inflammatory disorders were commonly reported in these patients.
While a contributory role for metreleptin in lymphoma development in patients with lipodystrophy cannot be excluded, our analysis suggests that lymphoma development may be associated with underlying pathophysiology that also leads to lipodystrophy rather than the pharmacological actions of metreleptin. Our findings support the view that, in some instances, immunoproliferative disorders of T-cells may contribute to syndromes involving autoimmune processes, including AGL. |
|---|---|
| AbstractList | Metreleptin is a form of leptin replacement therapy used with diet and lifestyle modifications to treat the metabolic complications of leptin deficiency in lipodystrophy, a rare disease characterized by adipose tissue deficiency. Previously, identification of T-cell lymphomas in three metreleptin-treated patients with acquired generalized lipodystrophy (AGL) suggested a possible relationship between metreleptin and lymphoma development. To further investigate this, we performed a real-world pharmacovigilance assessment and literature review to identify lymphomas in patients with lipodystrophy and congenital leptin deficiency (CLD) who were either metreleptin-naïve, or who had previously received/were receiving metreleptin at the time of lymphoma diagnosis.IntroductionMetreleptin is a form of leptin replacement therapy used with diet and lifestyle modifications to treat the metabolic complications of leptin deficiency in lipodystrophy, a rare disease characterized by adipose tissue deficiency. Previously, identification of T-cell lymphomas in three metreleptin-treated patients with acquired generalized lipodystrophy (AGL) suggested a possible relationship between metreleptin and lymphoma development. To further investigate this, we performed a real-world pharmacovigilance assessment and literature review to identify lymphomas in patients with lipodystrophy and congenital leptin deficiency (CLD) who were either metreleptin-naïve, or who had previously received/were receiving metreleptin at the time of lymphoma diagnosis.Cases were identified from PubMed, Embase and the Cochrane Library (from database inception through to November 22, 2024), and through review of 11 years post-marketing data from the global safety database (GSD) of the marketing authorization holder for metreleptin.MethodsCases were identified from PubMed, Embase and the Cochrane Library (from database inception through to November 22, 2024), and through review of 11 years post-marketing data from the global safety database (GSD) of the marketing authorization holder for metreleptin.The final analysis set comprised 17 lymphomas in 16 patients reported in 11 published articles and one GSD case report. Twelve lymphomas were recorded in 12 metreleptin-naïve patients - these comprised six T-cell lymphomas (one each in six patients with AGL), three B-cell lymphomas (in two patients with familial partial lipodystrophy and one patient with AGL), and three Hodgkin lymphomas (separately reported in one patient each with generalized lipodystrophy, juvenile-onset dermatomyositis-associated lipodystrophy, and CLD). Five lymphomas were identified in four metreleptin-treated patients, three of whom (all with AGL and T-cell lymphomas) were reported in previously published studies. The remaining metreleptin-treated patient (from the GSD) had generalized lipodystrophy-associated atypical progeroid syndrome and developed a B-cell lymphoma and brain lymphoma following solid organ transplantation and immunosuppressant therapy. All nine T-cell lymphomas occurred in patients with AGL, and additional autoimmune and/or inflammatory disorders were commonly reported in these patients.ResultsThe final analysis set comprised 17 lymphomas in 16 patients reported in 11 published articles and one GSD case report. Twelve lymphomas were recorded in 12 metreleptin-naïve patients - these comprised six T-cell lymphomas (one each in six patients with AGL), three B-cell lymphomas (in two patients with familial partial lipodystrophy and one patient with AGL), and three Hodgkin lymphomas (separately reported in one patient each with generalized lipodystrophy, juvenile-onset dermatomyositis-associated lipodystrophy, and CLD). Five lymphomas were identified in four metreleptin-treated patients, three of whom (all with AGL and T-cell lymphomas) were reported in previously published studies. The remaining metreleptin-treated patient (from the GSD) had generalized lipodystrophy-associated atypical progeroid syndrome and developed a B-cell lymphoma and brain lymphoma following solid organ transplantation and immunosuppressant therapy. All nine T-cell lymphomas occurred in patients with AGL, and additional autoimmune and/or inflammatory disorders were commonly reported in these patients.While a contributory role for metreleptin in lymphoma development in patients with lipodystrophy cannot be excluded, our analysis suggests that lymphoma development may be associated with underlying pathophysiology that also leads to lipodystrophy rather than the pharmacological actions of metreleptin. Our findings support the view that, in some instances, immunoproliferative disorders of T-cells may contribute to syndromes involving autoimmune processes, including AGL.DiscussionWhile a contributory role for metreleptin in lymphoma development in patients with lipodystrophy cannot be excluded, our analysis suggests that lymphoma development may be associated with underlying pathophysiology that also leads to lipodystrophy rather than the pharmacological actions of metreleptin. Our findings support the view that, in some instances, immunoproliferative disorders of T-cells may contribute to syndromes involving autoimmune processes, including AGL. IntroductionMetreleptin is a form of leptin replacement therapy used with diet and lifestyle modifications to treat the metabolic complications of leptin deficiency in lipodystrophy, a rare disease characterized by adipose tissue deficiency. Previously, identification of T-cell lymphomas in three metreleptin-treated patients with acquired generalized lipodystrophy (AGL) suggested a possible relationship between metreleptin and lymphoma development. To further investigate this, we performed a real-world pharmacovigilance assessment and literature review to identify lymphomas in patients with lipodystrophy and congenital leptin deficiency (CLD) who were either metreleptin-naïve, or who had previously received/were receiving metreleptin at the time of lymphoma diagnosis.MethodsCases were identified from PubMed, Embase and the Cochrane Library (from database inception through to November 22, 2024), and through review of 11 years post-marketing data from the global safety database (GSD) of the marketing authorization holder for metreleptin.ResultsThe final analysis set comprised 17 lymphomas in 16 patients reported in 11 published articles and one GSD case report. Twelve lymphomas were recorded in 12 metreleptin-naïve patients — these comprised six T-cell lymphomas (one each in six patients with AGL), three B-cell lymphomas (in two patients with familial partial lipodystrophy and one patient with AGL), and three Hodgkin lymphomas (separately reported in one patient each with generalized lipodystrophy, juvenile-onset dermatomyositis-associated lipodystrophy, and CLD). Five lymphomas were identified in four metreleptin-treated patients, three of whom (all with AGL and T-cell lymphomas) were reported in previously published studies. The remaining metreleptin-treated patient (from the GSD) had generalized lipodystrophy-associated atypical progeroid syndrome and developed a B-cell lymphoma and brain lymphoma following solid organ transplantation and immunosuppressant therapy. All nine T-cell lymphomas occurred in patients with AGL, and additional autoimmune and/or inflammatory disorders were commonly reported in these patients.DiscussionWhile a contributory role for metreleptin in lymphoma development in patients with lipodystrophy cannot be excluded, our analysis suggests that lymphoma development may be associated with underlying pathophysiology that also leads to lipodystrophy rather than the pharmacological actions of metreleptin. Our findings support the view that, in some instances, immunoproliferative disorders of T-cells may contribute to syndromes involving autoimmune processes, including AGL. Metreleptin is a form of leptin replacement therapy used with diet and lifestyle modifications to treat the metabolic complications of leptin deficiency in lipodystrophy, a rare disease characterized by adipose tissue deficiency. Previously, identification of T-cell lymphomas in three metreleptin-treated patients with acquired generalized lipodystrophy (AGL) suggested a possible relationship between metreleptin and lymphoma development. To further investigate this, we performed a real-world pharmacovigilance assessment and literature review to identify lymphomas in patients with lipodystrophy and congenital leptin deficiency (CLD) who were either metreleptin-naïve, or who had previously received/were receiving metreleptin at the time of lymphoma diagnosis. Cases were identified from PubMed, Embase and the Cochrane Library (from database inception through to November 22, 2024), and through review of 11 years post-marketing data from the global safety database (GSD) of the marketing authorization holder for metreleptin. The final analysis set comprised 17 lymphomas in 16 patients reported in 11 published articles and one GSD case report. Twelve lymphomas were recorded in 12 metreleptin-naïve patients - these comprised six T-cell lymphomas (one each in six patients with AGL), three B-cell lymphomas (in two patients with familial partial lipodystrophy and one patient with AGL), and three Hodgkin lymphomas (separately reported in one patient each with generalized lipodystrophy, juvenile-onset dermatomyositis-associated lipodystrophy, and CLD). Five lymphomas were identified in four metreleptin-treated patients, three of whom (all with AGL and T-cell lymphomas) were reported in previously published studies. The remaining metreleptin-treated patient (from the GSD) had generalized lipodystrophy-associated atypical progeroid syndrome and developed a B-cell lymphoma and brain lymphoma following solid organ transplantation and immunosuppressant therapy. All nine T-cell lymphomas occurred in patients with AGL, and additional autoimmune and/or inflammatory disorders were commonly reported in these patients. While a contributory role for metreleptin in lymphoma development in patients with lipodystrophy cannot be excluded, our analysis suggests that lymphoma development may be associated with underlying pathophysiology that also leads to lipodystrophy rather than the pharmacological actions of metreleptin. Our findings support the view that, in some instances, immunoproliferative disorders of T-cells may contribute to syndromes involving autoimmune processes, including AGL. |
| Author | Walkovich, Kelly J. Oral, Elif A. Akinci, Baris Brown, Rebecca J. Araujo-Vilar, David Magee, David A. Barbarosie, Alexandru |
| AuthorAffiliation | 3 Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Michigan , Ann Arbor, MI , United States 6 Metabolism, Endocrinology and Diabetes Division, Department of Internal Medicine, Caswell Diabetes Institute, North Campus Research Complex, University of Michigan , Ann Arbor, MI , United States 2 UETeM−Molecular Pathology of Rare Diseases Group, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), School of Medicine and Dentistry, University of Santiago de Compostela , Santiago de Compostela , Spain 5 Izmir Biomedicine and Genome Center & Dokuz Eylul University Technopark (DEPARK), Dokuz Eylul University Health Campus , Izmir , Türkiye 4 Chiesi Global Rare Diseases , Dublin , Ireland 1 Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD , United States |
| AuthorAffiliation_xml | – name: 2 UETeM−Molecular Pathology of Rare Diseases Group, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), School of Medicine and Dentistry, University of Santiago de Compostela , Santiago de Compostela , Spain – name: 6 Metabolism, Endocrinology and Diabetes Division, Department of Internal Medicine, Caswell Diabetes Institute, North Campus Research Complex, University of Michigan , Ann Arbor, MI , United States – name: 4 Chiesi Global Rare Diseases , Dublin , Ireland – name: 3 Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Michigan , Ann Arbor, MI , United States – name: 5 Izmir Biomedicine and Genome Center & Dokuz Eylul University Technopark (DEPARK), Dokuz Eylul University Health Campus , Izmir , Türkiye – name: 1 Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD , United States |
| Author_xml | – sequence: 1 givenname: Rebecca J. surname: Brown fullname: Brown, Rebecca J. – sequence: 2 givenname: David surname: Araujo-Vilar fullname: Araujo-Vilar, David – sequence: 3 givenname: Kelly J. surname: Walkovich fullname: Walkovich, Kelly J. – sequence: 4 givenname: Alexandru surname: Barbarosie fullname: Barbarosie, Alexandru – sequence: 5 givenname: David A. surname: Magee fullname: Magee, David A. – sequence: 6 givenname: Baris surname: Akinci fullname: Akinci, Baris – sequence: 7 givenname: Elif A. surname: Oral fullname: Oral, Elif A. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40469440$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkstu3CAUhlGUqLk0L5BF5WU3nnC1zaqKol4iReqmWSMMhzERNi54Jpq3L5mZRgmIi-DjP3D4L9HpFCdA6IbgFWOdvHUw2biimIoVER1tiThBF6RpeE2ZpKfv5ufoOudnXArHRMruEzrnmDeSc3yBhrsqgQ71S0zBVvOg06hN3Pq1D3oyUOmcIecRpqXSk62CXyDpZZOgHNt6eKmiq8JunIc46srCFkKc97SfCjxHu8tLivOw-4zOnA4Zro_jFXr68f3P_a_68ffPh_u7x9pwSpe677htWkb7xpnGUNFzKYwrleOWGstMA5xzVpCOccMdA9a5XrStxFCaZFfo4aBro35Wc_KjTjsVtVf7hZjWSqfFmwCq6XRvLO9boXveWiddzzpeMikkcVjqovXtoDVv-hGsKe9KOnwQ_bgz-UGt41YRShgT-9t8PSqk-HcDeVGjzwZCSS7ETVaMEiG7pvQF_fI-2FuU_39VAHoATIo5J3BvCMHq1RNq7wn16gl19AT7B1x1rRg |
| Cites_doi | 10.2147/DMSO.S130810 10.2337/db21-1086 10.3109/10428194.2015.1040015 10.1111/dom.15882 10.3389/fendo.2023.1250203 10.1056/NEJMra1702693 10.1210/jcemcr/luae069 10.1007/s12020-019-01862-8 10.1371/journal.pone.0199052 10.1158/1055-9965.EPI-06-1069 10.1056/NEJMra025261 10.1172/JCI15693 10.1158/1055-9965.EPI-06-0300 10.3389/fimmu.2018.02142 10.1210/jc.2017-02078 10.3389/fimmu.2020.622468 10.1016/j.imlet.2023.08.007 10.1038/29795 10.1007/s12020-018-1589-1 10.1210/jc.2016-2466 10.1038/ng0398-213 10.1016/j.nmd.2018.06.011 10.1016/j.ecl.2017.01.012 10.1210/jendso/bvac150.065 10.1038/bjc.2015.94 10.1210/jcem.84.10.5999 10.1210/jc.2018-02730 10.1007/s12020-014-0450-4 10.1210/jc.2011-1159 10.1007/s40265-013-0074-7 10.1080/17446651.2020.1735360 10.1038/s42255-019-0095-y 10.1001/archinte.1978.03630330097036 10.1016/j.semcancer.2013.12.001 10.1210/jendso/bvaa046.1059 10.1210/clinem/dgae149 10.1186/s40842-019-0076-9 10.1210/jc.2005-1220 10.1016/j.eclinm.2022.101674 10.1038/43185 10.4158/ACCR-2019-0366 10.2169/internalmedicine.53.1713 10.3390/medsci9010005 10.1002/art.21675 10.1097/00005792-200303000-00007 10.1210/jcem.87.5.8624 10.1111/j.1365-2796.2008.02029.x 10.1111/ijd.12185 10.1111/j.1365-4632.2006.02888.x 10.1097/01.md.0000111061.69212.59 10.1007/978-1-62703-170-7_2 10.1096/fsb2fasebj.12.1.57 10.1056/NEJMoa012437 10.1056/NEJMoa2204041 10.1056/NEJM199909163411204 |
| ContentType | Journal Article |
| Copyright | Copyright © 2025 Brown, Araujo-Vilar, Walkovich, Barbarosie, Magee, Akinci and Oral. Copyright © 2025 Brown, Araujo-Vilar, Walkovich, Barbarosie, Magee, Akinci and Oral 2025 Brown, Araujo-Vilar, Walkovich, Barbarosie, Magee, Akinci and Oral |
| Copyright_xml | – notice: Copyright © 2025 Brown, Araujo-Vilar, Walkovich, Barbarosie, Magee, Akinci and Oral. – notice: Copyright © 2025 Brown, Araujo-Vilar, Walkovich, Barbarosie, Magee, Akinci and Oral 2025 Brown, Araujo-Vilar, Walkovich, Barbarosie, Magee, Akinci and Oral |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.3389/fendo.2025.1582715 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1664-2392 |
| ExternalDocumentID | oai_doaj_org_article_68abcd4b75ab47df9fb384715591f09a PMC12133509 40469440 10_3389_fendo_2025_1582715 |
| Genre | Journal Article Review |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE KQ8 M~E OK1 PGMZT RPM ACXDI CGR CUY CVF ECM EIF IPNFZ M48 NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c422t-b84d6732b6fc6c25b495cfcfc4072cd3c6e4443673834c4f3e38fb57790e79093 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001503827400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1664-2392 |
| IngestDate | Fri Oct 03 12:43:40 EDT 2025 Thu Aug 21 18:25:41 EDT 2025 Fri Sep 05 15:55:25 EDT 2025 Thu Jun 19 02:16:00 EDT 2025 Sat Nov 29 07:51:21 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | acquired generalized lipodystrophy autoimmunity B cell lymphoma lymphoma metreleptin pharmacovigilance T-cell lymphoma lipodystrophy |
| Language | English |
| License | Copyright © 2025 Brown, Araujo-Vilar, Walkovich, Barbarosie, Magee, Akinci and Oral. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c422t-b84d6732b6fc6c25b495cfcfc4072cd3c6e4443673834c4f3e38fb57790e79093 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 Edited by: Tao Zhang, West China Hospital, China Brigitte Delemer, Université de Reims Champagne-Ardenne, France Reviewed by: Elif Ozsu, Ankara University Medical School, Türkiye |
| OpenAccessLink | https://doaj.org/article/68abcd4b75ab47df9fb384715591f09a |
| PMID | 40469440 |
| PQID | 3215986215 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_68abcd4b75ab47df9fb384715591f09a pubmedcentral_primary_oai_pubmedcentral_nih_gov_12133509 proquest_miscellaneous_3215986215 pubmed_primary_40469440 crossref_primary_10_3389_fendo_2025_1582715 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-05-21 |
| PublicationDateYYYYMMDD | 2025-05-21 |
| PublicationDate_xml | – month: 05 year: 2025 text: 2025-05-21 day: 21 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in endocrinology (Lausanne) |
| PublicationTitleAlternate | Front Endocrinol (Lausanne) |
| PublicationYear | 2025 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Garg (B3) 2011; 96 B22 B23 Wang (B36) 2013 Corvillo (B5) 2023; 72 B24 B25 Chou (B21) 2013; 73 B26 B27 Kolijn (B49) 2023; 263 Yiannias (B55) 2006; 45 Lima (B48) 2018; 13 Oral (B18) 2002; 346 Kiernan (B45) 2020; 11 Oral (B46) 2006; 91 Misra (B7) 2003; 82 Hoff (B42) 2024; 2 B31 Brown (B1) 2016; 101 Friedman (B9) 2019; 1 Montague (B15) 1997; 387 Baecklund (B37) 2006; 54 Garg (B2) 2004; 350 von Schnurbein (B17) 2024; 109 Ozata (B47) 1999; 84 Thandra (B53) 2021; 9 Smedby (B39) 2006; 15 Funcke (B29) 2023; 388 Lightbourne (B6) 2017; 46 Strobel (B16) 1998; 18 Oral (B20) 2019; 64 Araujo-Vilar (B32) 2015; 49 de Andrade (B59) 2020; 6 Corvillo (B40) 2018; 9 Baecklund (B41) 2014; 24 Hall (B62) 1978; 138 Torchen (B64); 4 Brown (B19) 2018; 60 Haque (B10) 2002; 87 Fernandez-Pombo (B13) 2024; 26 Farooqi (B14) 1999; 341 Akinci (B11) 2019; 104 Rego de Figueiredo (B61) 2018; 28 Foss-Freitas (B54) 2020; 15 Smith (B35) 2015; 112 Aslam (B56) 2015; 54 Chiquette (B34) 2017; 10 Torchen (B63); 6 Krishnan (B51) 2007; 16 Loffreda (B43) 1998; 12 Akinci (B4) 2000 Dierickx (B50) 2018; 378 Smedby (B38) 2008; 264 Misra (B8) 2004; 83 Brown (B30) 2016; 57 Fernandez-Pombo (B12) 2023; 14 Lord (B44) 1998; 394 Farooqi (B28) 2002; 110 Hussain (B33) 2018; 103 Esfandiari (B57) 2019; 5 Ebihara (B58) Donzel (B52) 2022; 54 Iwanishi (B60) 2014; 53 |
| References_xml | – volume: 10 year: 2017 ident: B34 article-title: Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges publication-title: Diabetes Metab Syndr Obes doi: 10.2147/DMSO.S130810 – volume: 72 start-page: 71 year: 2023 ident: B5 article-title: Characterization and clinical association of autoantibodies against perilipin 1 in patients with acquired generalized lipodystrophy publication-title: Diabetes doi: 10.2337/db21-1086 – volume: 57 start-page: 45 year: 2016 ident: B30 article-title: Lymphoma in acquired generalized lipodystrophy publication-title: Leuk Lymphoma doi: 10.3109/10428194.2015.1040015 – volume: 26 year: 2024 ident: B13 article-title: A cohort analysis of familial partial lipodystrophy from two mediterranean countries publication-title: Diabetes Obes Metab doi: 10.1111/dom.15882 – volume: 14 year: 2023 ident: B12 article-title: Natural history and comorbidities of generalized and partial lipodystrophy syndromes in Spain publication-title: Front Endocrinol (Lausanne) doi: 10.3389/fendo.2023.1250203 – volume: 378 year: 2018 ident: B50 article-title: Post-transplantation lymphoproliferative disorders in adults publication-title: N Engl J Med doi: 10.1056/NEJMra1702693 – volume: 2 year: 2024 ident: B42 article-title: A novel subtype of acquired generalized lipodystrophy associated with subcutaneous panniculitis-like T-cell lymphoma publication-title: JCEM Case Rep doi: 10.1210/jcemcr/luae069 – ident: B25 – volume: 64 year: 2019 ident: B20 article-title: Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy publication-title: Endocrine doi: 10.1007/s12020-019-01862-8 – volume: 13 year: 2018 ident: B48 article-title: Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy publication-title: PloS One doi: 10.1371/journal.pone.0199052 – volume: 16 year: 2007 ident: B51 article-title: Non-hodgkin lymphoma secondary to cancer chemotherapy publication-title: Cancer Epidemiol Biomarkers Prev doi: 10.1158/1055-9965.EPI-06-1069 – ident: B31 – volume: 350 year: 2004 ident: B2 article-title: Acquired and inherited lipodystrophies publication-title: N Engl J Med doi: 10.1056/NEJMra025261 – volume: 110 year: 2002 ident: B28 article-title: Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency publication-title: J Clin Invest doi: 10.1172/JCI15693 – volume: 15 year: 2006 ident: B39 article-title: Malignant lymphomas in autoimmunity and inflammation: A review of risks, risk factors, and lymphoma characteristics publication-title: Cancer Epidemiol Biomarkers Prev doi: 10.1158/1055-9965.EPI-06-0300 – volume: 9 year: 2018 ident: B40 article-title: Autoantibodies against perilipin 1 as a cause of acquired generalized lipodystrophy publication-title: Front Immunol doi: 10.3389/fimmu.2018.02142 – volume: 103 year: 2018 ident: B33 article-title: A novel generalized lipodystrophy-associated progeroid syndrome due to recurrent heterozygous LMNA P.T10i mutation publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2017-02078 – volume: 11 year: 2020 ident: B45 article-title: The role of the adipokine leptin in immune cell function in health and disease publication-title: Front Immunol doi: 10.3389/fimmu.2020.622468 – volume: 263 start-page: 46 year: 2023 ident: B49 article-title: Immune dysregulation as a leading principle for lymphoma development in diverse immunological backgrounds publication-title: Immunol Lett doi: 10.1016/j.imlet.2023.08.007 – volume: 394 start-page: 897 year: 1998 ident: B44 article-title: Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression publication-title: Nature doi: 10.1038/29795 – volume: 60 year: 2018 ident: B19 article-title: Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy publication-title: Endocrine doi: 10.1007/s12020-018-1589-1 – volume: 101 year: 2016 ident: B1 article-title: The diagnosis and management of lipodystrophy syndromes: A multi-society practice guideline publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2016-2466 – volume: 18 year: 1998 ident: B16 article-title: A leptin missense mutation associated with hypogonadism and morbid obesity publication-title: . Nat Genet doi: 10.1038/ng0398-213 – volume: 28 year: 2018 ident: B61 article-title: Juvenile dermatomyositis forty years on: case report publication-title: Neuromuscul Disord doi: 10.1016/j.nmd.2018.06.011 – volume: 46 year: 2017 ident: B6 article-title: Genetics of lipodystrophy publication-title: Endocrinol Metab Clin North Am doi: 10.1016/j.ecl.2017.01.012 – volume: 6 ident: B63 article-title: Lymphoma in congenital leptin deficiency: comorbidity or adverse effect doi: 10.1210/jendso/bvac150.065 – ident: B24 – volume: 112 year: 2015 ident: B35 article-title: Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy research network publication-title: Br J Cancer doi: 10.1038/bjc.2015.94 – volume: 84 year: 1999 ident: B47 article-title: Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem.84.10.5999 – volume: 104 year: 2019 ident: B11 article-title: Comorbidities and survival in patients with lipodystrophy: an international chart review study publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2018-02730 – volume: 49 year: 2015 ident: B32 article-title: Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term spanish experience publication-title: Endocrine doi: 10.1007/s12020-014-0450-4 – volume: 96 year: 2011 ident: B3 article-title: Clinical review: lipodystrophies: genetic and acquired body fat disorders publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2011-1159 – volume: 73 year: 2013 ident: B21 article-title: Metreleptin: first global approval publication-title: Drugs doi: 10.1007/s40265-013-0074-7 – volume: 15 start-page: 95 year: 2020 ident: B54 article-title: Diagnostic strategies and clinical management of lipodystrophy publication-title: Expert Rev Endocrinol Metab doi: 10.1080/17446651.2020.1735360 – volume: 1 year: 2019 ident: B9 article-title: Leptin and the endocrine control of energy balance publication-title: Nat Metab doi: 10.1038/s42255-019-0095-y – volume: 138 year: 1978 ident: B62 article-title: Generalized lipodystrophy, scleroderma, and hodgkin’s disease publication-title: Arch Intern Med doi: 10.1001/archinte.1978.03630330097036 – volume: 24 start-page: 61 year: 2014 ident: B41 article-title: Lymphoma development in patients with autoimmune and inflammatory disorders–what are the driving forces publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2013.12.001 – volume: 4 ident: B64 article-title: Congenital leptin deficiency: clinical insights from the first reported US cases doi: 10.1210/jendso/bvaa046.1059 – volume-title: Lipodystrophy syndromes: presentation and treatment year: 2000 ident: B4 – volume: 109 year: 2024 ident: B17 article-title: Classification of congenital leptin deficiency publication-title: J Clin Endocrinol Metab doi: 10.1210/clinem/dgae149 – ident: B27 – volume: 5 year: 2019 ident: B57 article-title: Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to metreleptin publication-title: Clin Diabetes Endocrinol doi: 10.1186/s40842-019-0076-9 – ident: B23 – volume: 91 year: 2006 ident: B46 article-title: Leptin replacement therapy modulates circulating lymphocyte subsets and cytokine responsiveness in severe lipodystrophy publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2005-1220 – volume: 54 year: 2022 ident: B52 article-title: Lymphomas associated with epstein-barr virus infection in 2020: results from a large, unselected case series in France publication-title: EClinicalMedicine doi: 10.1016/j.eclinm.2022.101674 – volume: 387 year: 1997 ident: B15 article-title: Congenital leptin deficiency is associated with severe early-onset obesity in humans publication-title: Nature doi: 10.1038/43185 – volume: 6 year: 2020 ident: B59 article-title: Unusual presentations of LMNA-associated lipodystrophy with complex phenotypes and generalized fat loss: when the genetic diagnosis uncovers novel features publication-title: AACE Clin Case Rep doi: 10.4158/ACCR-2019-0366 – volume: 53 year: 2014 ident: B60 article-title: Primary intestinal follicular lymphoma and premature atherosclerosis in a Japanese diabetic patient with atypical familial partial lipodystrophy publication-title: Intern Med doi: 10.2169/internalmedicine.53.1713 – volume: 9 start-page: 20210130 year: 2021 ident: B53 article-title: Epidemiology of non-hodgkin’s lymphoma publication-title: Med Sci (Basel) doi: 10.3390/medsci9010005 – volume: 54 start-page: 692 year: 2006 ident: B37 article-title: Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis publication-title: Arthritis Rheum doi: 10.1002/art.21675 – volume: 82 year: 2003 ident: B7 article-title: Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature publication-title: Med (Baltimore) doi: 10.1097/00005792-200303000-00007 – volume: 87 start-page: 2395 year: 2002 ident: B10 article-title: Serum adiponectin and leptin levels in patients with lipodystrophies publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem.87.5.8624 – volume: 264 year: 2008 ident: B38 article-title: Autoimmune and inflammatory disorders and risk of Malignant lymphomas–an update publication-title: J Intern Med doi: 10.1111/j.1365-2796.2008.02029.x – volume-title: Endocrine Reviews ident: B58 – volume: 54 year: 2015 ident: B56 article-title: Acquired generalized lipodystrophy associated with peripheral T cell lymphoma with cutaneous infiltration publication-title: Int J Dermatol doi: 10.1111/ijd.12185 – ident: B26 – volume: 45 year: 2006 ident: B55 article-title: Peripheral T-cell lymphoma presenting as lipoatrophy and nodules publication-title: Int J Dermatol doi: 10.1111/j.1365-4632.2006.02888.x – volume: 83 start-page: 18 year: 2004 ident: B8 article-title: Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature publication-title: Med (Baltimore) doi: 10.1097/01.md.0000111061.69212.59 – start-page: 25 volume-title: T-cell lymphomas year: 2013 ident: B36 article-title: Epidemiology and prognosis of T-cell lymphoma doi: 10.1007/978-1-62703-170-7_2 – ident: B22 – volume: 12 start-page: 57 year: 1998 ident: B43 article-title: Leptin regulates proinflammatory immune responses publication-title: FASEB J doi: 10.1096/fsb2fasebj.12.1.57 – volume: 346 year: 2002 ident: B18 article-title: Leptin-replacement therapy for lipodystrophy publication-title: N Engl J Med doi: 10.1056/NEJMoa012437 – volume: 388 year: 2023 ident: B29 article-title: Rare antagonistic leptin variants and severe, early-onset obesity publication-title: N Engl J Med doi: 10.1056/NEJMoa2204041 – volume: 341 year: 1999 ident: B14 article-title: Effects of recombinant leptin therapy in a child with congenital leptin deficiency publication-title: N Engl J Med doi: 10.1056/NEJM199909163411204 |
| SSID | ssj0000401998 |
| Score | 2.3690157 |
| SecondaryResourceType | review_article |
| Snippet | Metreleptin is a form of leptin replacement therapy used with diet and lifestyle modifications to treat the metabolic complications of leptin deficiency in... IntroductionMetreleptin is a form of leptin replacement therapy used with diet and lifestyle modifications to treat the metabolic complications of leptin... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 1582715 |
| SubjectTerms | acquired generalized lipodystrophy Adult autoimmunity B cell lymphoma Endocrinology Female Humans Leptin - adverse effects Leptin - analogs & derivatives Leptin - therapeutic use lipodystrophy Lipodystrophy - complications Lipodystrophy - drug therapy lymphoma Lymphoma - chemically induced Lymphoma - epidemiology Male Middle Aged Pharmacovigilance T-cell lymphoma |
| Title | A real-world pharmacovigilance assessment and literature review of lymphoma development in lipodystrophy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40469440 https://www.proquest.com/docview/3215986215 https://pubmed.ncbi.nlm.nih.gov/PMC12133509 https://doaj.org/article/68abcd4b75ab47df9fb384715591f09a |
| Volume | 16 |
| WOSCitedRecordID | wos001503827400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1664-2392 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000401998 issn: 1664-2392 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1664-2392 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000401998 issn: 1664-2392 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEB3SUEovoW3aZvsRVOituNnVh20d05DQS0IOLexN6LMxbO1ldxPIJb-9M7Kz2S2FXIqxD7ZAYp4tvWdJbwA-ezfmqAJ44UXpCqm0Kizy5iIpr-XEISOvQk42UV1c1NOpvtxI9UVrwnp74D5wR2VtnQ_SVco6WYWkkxPUoyITnqSxztQIWc-GmMp9MMoGFBL9LhlUYfooxTbQZj-uvk5UzSvKg7sxEmXD_n-xzL8XS26MPmcvYG-gjey4b-5L2IntK3h2PkyM78PVMUP2NyuyASqbD37UN82vZkawMrs24GS2DWy2NlNm_d4V1iU2u0Vku9-WhYeFRKxpsfC8C7fL1aJDSF7Dz7PTHyffiyGJQuEl56vC1TKUleC0qaf0XDlURD7hQc5oPghfRimloOSfQnqZRBR1copsCCOeWryB3bZr4wEwVDsW5YqMKlipObdOI91MpbWBixjKEXy5D6iZ914ZBjUGhd_k8BsKvxnCP4JvFPN1SfK5zjcQfTOgbx5DfwSf7hEz-F3QZIdtY3e9NAK5jEa5RhW97RFcVyXpp4CU4xHUW9hutWX7SdtcZe9tcsATSLLe_Y_Wv4fnFBFajMAnH2B3tbiOH-Gpv1k1y8UhPKmm9WF-r_F6fnf6B-qBAG8 |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+real-world+pharmacovigilance+assessment+and+literature+review+of+lymphoma+development+in+lipodystrophy&rft.jtitle=Frontiers+in+endocrinology+%28Lausanne%29&rft.au=Brown%2C+Rebecca+J.&rft.au=Araujo-Vilar%2C+David&rft.au=Walkovich%2C+Kelly+J.&rft.au=Barbarosie%2C+Alexandru&rft.date=2025-05-21&rft.issn=1664-2392&rft.eissn=1664-2392&rft.volume=16&rft_id=info:doi/10.3389%2Ffendo.2025.1582715&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fendo_2025_1582715 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-2392&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-2392&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-2392&client=summon |